DUBLIN--(BUSINESS WIRE)--The "Generalized Tonic-Clonic Seizure Ongoing Global Clinical Trials Analysis and Outlook" report has been added to ResearchAndMarkets.com's offering. Generalized Tonic-Clonic ...

-- New approval for VIMPAT® (lacosamide) CV in the U.S. as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS) in patients four years of age and older -- All three ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. DENVER — Primary generalized tonic-clonic seizures ...

FINTEPLA is approved by the U.S. Food and Drug Administration (FDA) for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients two years of age and older 1 ...

LONDON--(BUSINESS WIRE)-- LivaNova PLC (LIVN), a market-leading medical technology company, today announced that 24-month data on generalized tonic-clonic (GTC) seizures in people with drug-resistant ...

Eisai announced results from a Phase 3 Study 332 trial of perampanel, an AMPA receptor antagonist in patients with primary generalized tonic-clonic (PGTC) seizures. Study 332 was a double-blind, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The study included 426 women with IGE or tonic-clonic ...

The FDA also approved Vimpat Injection for use in pediatric patients 4 years of age and older. The Food and Drug Administration (FDA) has approved Vimpat ® (lacosamide; UCB) as adjunctive therapy in ...

MOUNTAIN VIEW, Calif., December 08, 2025--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, announced the ...

ATLANTA, June 24, 2024 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that Epilepsia published findings from a comprehensive scoping review examining the efficacy of ...